Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ceralasertib (AZD6738) in combination with durvalumab (MEDI4736) for metastatic solid tumors as salvage treatment
KCT0003806Phase 2Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ceralasertib and durvalumab in gastric adenocarcinoma, melanoma and Metastatic solid neoplasm (2 cohorts), sponsored by Samsung Medical Center. Started Aug 2019; status: active, not recruiting.
02
Drugs
ceralasertibdurvalumab
03
Conditions
gastric adenocarcinomamelanomaMetastatic solid neoplasm
Beyond the preview
Go deeper on KCT0003806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003806.